AstraZeneca’s camizestrant (Etcamah) cleared a major regulatory hurdle in the U.S., receiving accelerated approval for certain patients with HR+/HER2- advanced breast cancer with ESR1 mutations detected during aromatase inhibitor plus CDK4/6 inhibitor therapy. The FDA decision reverses an advisory committee vote against the drug earlier this year.